Abemaciclib is a small molecule inhibitor of cyclin-dependent kinase (CDK)4 and CDK6 in Phase III development for non-small cell lung cancer and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer by Eli Lilly. In normal tissues, CDK4/6 associate with cyclin-D proteins to phosphorylate and inactivate the retinoblastoma 1 (RB1) tumor suppressor protein, thereby releasing transcription factors needed for DNA replication and subsequent progression through the cell cycle. CDK4/6 are attractive targets as dysregulation of the cell cycle through genetic alterations is a hallmark of several cancers, including breast cancer. Inhibiting the phosphorylation of RB1 arrests cell growth in the G1 phase, preventing further cell growth and proliferation in malignant tissues.
4 Drug Overview
5 Product Profiles
5 abemaciclib : Breast cancer: HR+/HER2-
LIST OF FIGURES
10 Figure 1: Abemaciclib for HR+/HER2- breast cancer – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of abemaciclib in HR+/HER2- breast cancer
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of abemaciclib in HR+/HER2- breast cancer
LIST OF TABLES
6 Table 1: Abemaciclib drug profile
7 Table 2: Abemaciclib Phase III trial in HR+/HER2- breast cancer
9 Table 3: Abemaciclib Phase II trial in HR+/HER2- breast cancer
9 Table 4: Early-phase data for abemaciclib in HR+/HER2- breast cancer
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.